| Disease Sciences, Inc. to Research Cleaning the Food and
Blood Supplies Of Scrapie Infectivity, the Agent Believed to Cause Mad
BOCA RATON, Fla (PRNewswire) - Disease Sciences, Inc. (OTC Bulletin Board: DISE - news) announced today that it has entered into a research agreement with Dr. Paul Brown. The Company will be funding a research study to clean the meat and plasma (blood) supply of scrapie infectivity, the agent believed to cause Transmissible Spongiform Encephalopathies (TSE's). The most commonly known TSE's are, Bovine Spongiform Encephalopathy (``BSE'') in cattle, (commonly known as ``mad-cow disease''), Scrapie in sheep, Chronic Wasting Disease (``CWD'') in wild deer and elk and Creutzfeldt-Jakob Disease (``CJD'') in humans. A technology based on exposure to ultra-high pressure pulses has been shown to disinfect all conventional pathogens. This technology will be used to explore the inactivating effect of ultra-high pressure pulses on meat and plasma contaminated by the Scrapie agent.
``For many years the problem of inactivating the agents causing Transmissible Spongiform Encephalopathy has engaged the scientific community. The problem is particularly difficult when biological materials are at issue (e.g., blood products) and the recent breakout of variant CJD due to the consumption of tainted beef has raised the issue anew with the food industry,'' stated Dr. Paul Brown.
``With the recent blood bans from donors in the UK by the Red Cross over fears of Mad Cow Disease transmissibility, New York City has had its blood supply decreased by 25%. Combined with the terrorist attacks on the World Trade Center there could be serious blood supply shortages. These techniques may be able to clean food and blood supplies infected with these deadly TSE's. Should the results of these experiments come out as expected, Disease Sciences will file patents on these processes and will be at the forefront of the race to eliminate the transmission of these deadly diseases,'' stated Dr. Wayne Goldstein CEO.
About Disease Sciences Inc.
Disease Sciences, Inc. is a developmental stage biopharmaceutical/clinical diagnostics Company planning to employ a broad array of technologies to detect, identify and quantify substances in blood or other bodily fluids and tissues. Its primary goal will be a Transmissible Spongiform Encephalopathy (``TSE'') test, useful in the diagnosis of TSE diseases such as Bovine Spongiform Encephalopathy (``BSE'') in cattle, (commonly known as ``mad-cow disease''), Scrapie in sheep, Chronic Wasting Disease (``CWD'') in wild deer and elk and Creutzfeldt-Jakob Disease (``CJD'') in humans. Test results are to be used in the diagnosis, detection, evaluation, monitoring and potential treatment of diseases and other medical conditions. The Company intends to derive its revenues from patent sub-licensing fees, royalties from pharmaceutical sales, appropriate milestone payments and research and development contracts. The Company maintains a website at www.diseasesciences.com.
Safe Harbor Act Disclaimer: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including, without limitation, successful implementation of the Company's business strategy and competition, any of which may cause actual results to differ materially from those described in the statements. In addition, other factors that could cause actual results to differ materially are discussed in t
SOURCE: Disease Sciences, Inc.